Casi Pharmaceuticals
OTC: CASIFBeijing · Founded 2023 · Incorporated in Cayman Islands · 1 known investors
CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells. It focuses on treatments for antibody-mediated organ transplant rejection and autoimmune diseases such as immune thrombocytopenia.
BiotechHealthtech
Founders & leadership
CW
Chunhua WangChief Operating Officer
WG
Wei GaoGeneral Counsel
HH
Hai HuangGlobal Chief Commercial Officer
AA
Alexander A. ZukiwskiChief Medical Officer
W(
Wei (Larry) ZhangPresident
WH
Wei-Wu HeChief Executive Officer, Chairman of the Board of Directors
AY
Alexander Y. WuNamed on SEC filing
ZS
Zhenbo SuNamed on SEC filing
TF
Thomas FolinsbeeNamed on SEC filing
XZ
Xuebo ZengNamed on SEC filing
KQ
Kun QianGlobal Controller
Investors · 1
Reported raises · per SEC filings
Form D private placements$35M disclosed across 5 rounds · 2024–2026
▶$5MraisedApr 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedApr 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James HuangDirector
- Barbara Krebs-PohlDirector
- Wei-Wu HeDirector
- Kun QianExecutive Officer
- Wei GaoExecutive Officer
- Thomas FolinsbeeDirector
- Wei (Larry) ZhangExecutive Officer
- Alexander Y. WuDirector
- Xuebo ZengDirector
- Chunhua WangExecutive Officer
- Zhenbo SuDirector
- Hai HuangExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Apr 2026
- Incorporated
- Other, Cayman Islands, 2023
- Federal exemptions
- 06b
▶$5MraisedFeb 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedFeb 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wei GaoExecutive Officer
- Alexander A. ZukiwskiExecutive Officer
- Hai HuangExecutive Officer
- Wei (Larry) ZhangExecutive Officer
- Barbara Krebs-PohlDirector
- Chunhua WangExecutive Officer
- Kun QianExecutive Officer
- Zhenbo SuDirector
- Thomas FolinsbeeDirector
- Xuebo ZengDirector
- James HuangDirector
- David CoryExecutive Officer, Director
- Wei-Wu HeDirector
- Alexander Y. WuDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Feb 2026
- Incorporated
- Other, Cayman Islands, 2023
- Federal exemptions
- 06b
▶$5MraisedJan 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJan 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wei-Wu HeDirector
- James HuangDirector
- Xuebo ZengDirector
- Barbara Krebs-PohlDirector
- Alexander Y. WuDirector
- Zhenbo SuDirector
- David CoryExecutive Officer, Director
- Chunhua WangExecutive Officer
- Thomas FolinsbeeDirector
- Hai HuangExecutive Officer
- Wei (Larry) ZhangExecutive Officer
- Kun QianExecutive Officer
- Wei GaoExecutive Officer
- Alexander A. ZukiwskiExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jan 2026
- Incorporated
- Other, Cayman Islands, 2023
- Federal exemptions
- 06b
▶$5MraisedJan 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJan 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wei GaoExecutive Officer
- Alexander A. ZukiwskiExecutive Officer
- Barbara Krebs-PohlDirector
- David CoryExecutive Officer, Director
- Chunhua WangExecutive Officer
- James HuangDirector
- Wei-Wu HeDirector
- Wei (Larry) ZhangExecutive Officer
- Hai HuangExecutive Officer
- Xuebo ZengDirector
- Kun QianExecutive Officer
- Alexander Y. WuDirector
- Zhenbo SuDirector
- Thomas FolinsbeeDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Dec 2025
- Incorporated
- Other, Cayman Islands, 2023
- Federal exemptions
- 06b
▶$15MraisedJul 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$15MraisedJul 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chunhua WangExecutive Officer
- Wei GaoExecutive Officer
- Alexander Y. WuDirector
- Zhenbo SuDirector
- Hai HuangExecutive Officer
- Kun QianExecutive Officer
- Thomas FolinsbeeDirector
- Xuebo ZengDirector
- Alexander A. ZukiwskiExecutive Officer
- Wei (Larry) ZhangExecutive Officer
- Wei-Wu HeExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- Sales commissions
- $900K
- Placement agents
- JEFFERIES LLC
- First sale
- Jun 2024
- Incorporated
- Other, Cayman Islands, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Casi Pharmaceuticals do?
- CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells. It focuses on treatments for antibody-mediated organ transplant rejection and autoimmune diseases such as immune thrombocytopenia.
- Who are Casi Pharmaceuticals's investors?
- Casi Pharmaceuticals's investors include Foresite Capital.
- How much funding has Casi Pharmaceuticals raised?
- Casi Pharmaceuticals has disclosed $35M raised across 5 rounds.
- Where is Casi Pharmaceuticals headquartered?
- Casi Pharmaceuticals is headquartered in Beijing.